Company:  SCICLONE PHARMACEUTICALS ... (SCLN)
Form Type:  10-Q
Filing Date:  11/9/2011 
CIK:  0000880771 
Address:  950 TOWER LANE
SUITE 900
 
City, State, Zip:  FOSTER CITY, California 94404-2125 
Telephone:  650-358-3456 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$4.76  
Change: 
0.09 (1.93%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$247.32M
Description of Business
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) is a United States (�US�)-headquartered, China-focused, specialty pharmaceutical company with a substantial commercial business and a product portfolio of therapies for oncology, infectious diseases and cardiovascular disorders. We are focused on continuing to grow our revenue and profitability in the future. Our business and corporate strategy is focused primarily on the People�s Republic of China (�China�) where we have built a solid reputation and established a strong brand through many years of experience marketing our lead product, ZADAXIN (thymalfasin). In addition, we have an established product promotion business model with large pharmaceutical partners and we are focused on establishing profitability in all of these collaborations. We believe our sales and marketing strengths position us to benefit from the long-term expansion of the pharmaceutical market in China.
Register for EDGAR Pro and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      Item 1. Financial Statements (Unaudited)
        BALANCE SHEET
        INCOME STATEMENT
        CASH FLOW
        Notes to Unaudited Condensed Consolidated Financial Statements
      Item 2. Management's Discussion and Analysis of Financial ...
      Item 3. Quantitative and Qualitative Disclosures About ...
      Item 4. Controls and Procedures
    PART II. OTHER INFORMATION
      Item 1. Legal Proceedings
      Item 1A. Risk Factors
      Item 2. Unregistered Sales of Equity Securities and Use of ...
      Item 3. Defaults Upon Senior Securities
      Item 5. Other Information
      Item 6. Exhibits
    SIGNATURE
    INDEX TO EXHIBITS
  EXHIBIT 10.1
  EXHIBIT 31.1
    RULE 13a-14(a) CERTIFICATION OF CHIEF EXECUTIVE OFFICER
  EXHIBIT 31.2
    RULE 13a-14(a) CERTIFICATION OF CHIEF FINANCIAL OFFICER
  EXHIBIT 32.1
    SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER
  EXHIBIT 32.2
    SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICER
BROKERAGE PARTNERS